Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 2, 2013, Pages 207-214

  Dubovsky, Steven L ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar depression; Drug combinations; Fluoxetine; OFC; Olanzapine

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CREATINE KINASE; FLUOXETINE PLUS OLANZAPINE; LAMOTRIGINE; NEUROTROPHIN 3; PLACEBO;

ALKALINE PHOSPHATASE BLOOD LEVEL; BINDING AFFINITY; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FOLLOW UP; GENE EXPRESSION; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; NONHUMAN; OPEN STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SENSITIVITY AND SPECIFICITY; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; SUICIDAL BEHAVIOR; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; BENZODIAZEPINES; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FLUOXETINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84872436795     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.761206     Document Type: Review

References (54)

1. Bobo WV, Shelton RC. Efficacy, safety and tolerability of SymbyaxAR for acute-phase management of treatment-resistant depression. Expert Rev Neurother 2010;10:651-70
2. Angst J, Azorin JM, Bowden CL, et al. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode. Arch Gen Psychiatry 2011;68:791-9
3. Dubovsky SL, Leonard K, Griswold K, et al. Bipolar disorder is common in depressed primary care patients. Postgrad Med 2011;123:129-33
4. Dubovsky SL. Clinical guide to psychotropic medications. WW Norton, New York; 2005
5. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-22 (Pubitemid 46658703)
6. Rybakowski JK. Bipolarity and inadequate response to antidepressant drugs: clinical and psychopharmacological perspective. J Affect Disord 2012;136:e13-19
7. Schneck CD, Miklowitz DJ, Miyahara S, et al. The prospective course of rapid cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry 2008;165:370-7 (Pubitemid 351704493)
8. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003;5:421-33 (Pubitemid 38072244)
9. Shi L, Thiebaud P, McCombs JS. The impact of unrecognized bipolar disorders for patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program. J Affect Disord 2004;82:373-83 (Pubitemid 39536169)
10. Ghaemi SN, Rosenquist KJ, Ko JY, et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 2004;161:163-5 (Pubitemid 38419324)
11. Vieta E, Gunther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011;14:1029-49
12. Daly JJ, Prudic J, Devanand DP, et al. ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disord 2001;3:95-104 (Pubitemid 32492597)
13. Grunhaus L, Schreiber S, Dolberg O, et al. Response to ECT in major depression: are there differences between unipolar and bipolar depression? Bipolar Disord 2002;4(Suppl 1):91-3
14. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the Bolder II study). J Clin Psychopharmacol 2006;26:600-9 (Pubitemid 44772737)
15. Dubovsky SL. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. J Clin Psychiatry 1994;55(Suppl):34-44 (Pubitemid 24081835)
16. Croxtall JD, Scott LJ. Olanzapine/fluoxetine. A review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs 2010;24:245-62
17. Barden N. Modulation of glucocorticoid receptor gene expression by antidepressant drugs. Pharmacopsychiatry 1996;29:12-22 (Pubitemid 26071333)
18. Hirsch-Rodriguez E, Imbesi M, Manev R, et al. The pattern of melatonin receptor expression in the brain may influence antidepressant treatment. Med Hypotheses 2007;69:120-4 (Pubitemid 46686944)
19. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4:682-90
20. Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370
21. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-9 (Pubitemid 36962615)
22. Shelton RC. Intracellular mechanisms of antidepressant drug action. Harv Rev Psychiatry 2000;8:161-74
23. Srinivasan V, Smits M, Spence W, et al. Melatonin in mood disorders. World J Biol Psychiatry 2006;7:138-51 (Pubitemid 44137014)
24. Tardito D, Perez J, Tiraboschi E, et al. Signaling pathways regulating gene expression, neuroplasticity and neurotrophic mechanisms in the action of antidepressants: a critical review. Pharmacol Rev 2006;58:115-34
25. Marx CE, Shampine LJ, Khisti RT, et al. Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Pharmacol Biochem Behav 2006;84:609-17 (Pubitemid 350081089)
26. Agostinho FR, Reus GZ, Stringari RB, et al. Olanzapine plus fluoxetine treatment increases Nt-3 protein levels in the rat prefrontal cortex. Neurosci Lett 2011;497:99-103
27. Agostinho FR, Scaini G, Ferreira GK, et al. Effects of olanzapine, fluoxetine, and olanzapine/fluoxetine on creatine kinase activity in rat brain. Brain Res Bull 2009;80:337-40
28. Seager MA, Huff KD, Barth VN, et al. Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biol Psychiatry 2004;55:1103-9 (Pubitemid 38680563)
29. Perrone JA, Chabla JM, Hallas BH, et al. Weight loss dynamics during combined fluoxetine and olanzapine treatment. BMC Pharmacol 2004;4:27-31
30. Gossen D, de Suray JM, Vandenhende F, et al. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002;4:E11
31. Citrome L, Stauffer VL, Chen L, et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol 2009;29:278-83
32. Molden E, Spigset O. Tobacco smoking and drug interactions. Tidsskr Nor Laegeforen 2009;129:632-3
33. Tamayo JM, Sutton VK, Mattei MA, et al. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression. An open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol 2009;29:358-61
34. Tohen M, Vieta E, Calabrese JR, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88 (Pubitemid 37429647)
35. Keck PEJ, Corya SA, Altshuler LL, et al. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J Clin Psychiatry 2005;66:611-16 (Pubitemid 40733704)
36. Bertschy F, Bertschy G, Bondolfi G, Aubry JM. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psychiatry 2004;65:1537-45
37. Dube S, Tollefson GD, Thase ME, et al. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord 2007;9:618-27 (Pubitemid 47365630)
38. Benazzi F, Berk M, Frye MA, et al. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. J Clin Psychiatry 2009;70:1424-31
39. Vieta E, Berk M, Wang W, et al. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord 2009;119:22-7
40. Corya SA, Perlis RH, Keck PEJ, et al. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry 2006;67:798-806 (Pubitemid 43946187)
41. Kemp DE, Ganocy SJ, Brecher M, et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord 2011;130:171-9
42. Citrome L. Olanzapine-fluoxetine combination for the treatment of bipolar depression. Expert Opin Pharmacother 2011;12:2751-8
43. Perlis RH, Adams D, Fijal B, et al. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. J Clin Psychiatry 2010;71:599-605
44. Brown E, McElroy SL, Keck PEJ, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006;67:1025-33 (Pubitemid 44230872)
45. Brown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs lamotrigine in the 6-month treatment of bipolar depression. Int J Neuropsychopharmacol 2009;12:773-82
46. Houston JP, Fijal B, Heinloth AN, Adams D. Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients. Psychiatry Res 2010;175:171-2
47. Degenhardt EK, Jamal HH, Tormey S, Case M. Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination. An analysis of 2 adult studies in treatment-resistant depression. J Clin Psychopharmacol 2011;31:337-40
48. Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 2009;70:387-96
49. Lipkovich I, Jacobson JG, Caldwell C, et al. Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials. Psychopharmacol Bull 2009;42:23-39
50. Gibbons RD, Brown CH, Hur K, et al. Suicidal thoughts and behavior with antidepressant treatment. Reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69:580-7
51. Berghoefer A, Kossmann B, Mueller-Oerlinghausen B. Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: a retrospective analysis over 15 years. Acta Psychiatr Scand 1996;93:349-54 (Pubitemid 26189158)
52. Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995;152:1130-8
53. Association AD, Association AP. Endocrinologists AAoC, Obesity NAAftSo. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
54. Dubovsky SL, Dubovsky AN. Psychotropic drug prescriber's survival guide: ethical prescribing in the age of big pharma. W.W. Norton, New York; 2007